Atn1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Atrophin 1 (ATN1) is a nuclear transcriptional co-repressor protein that plays critical roles in neuronal function. Pathogenic polyglutamine expansions cause Dentatorubral-pallidoluysian Atrophy (DRPLA), and altered ATN1 function is observed in several neurodegenerative diseases.
ATN1 (Atrophin 1) is a protein encoded by a gene located on chromosome 12p13.31. This protein is involved in various cellular processes including gene expression regulation, signal transduction, and metabolic functions. ATN1 plays important roles in neuronal function and is implicated in neurodegenerative diseases.
| Attribute |
Value |
| Protein Name |
Atrophin 1 |
| Gene Symbol |
ATN1 |
| UniProt ID |
O75576 |
| Molecular Weight |
170 kDa (full-length) |
| Subcellular Localization |
Nucleus |
| Protein Family |
Atrophin family |
| Tissue Specificity |
Brain (high expression) |
ATN1 contains:
- Polyglutamine tract: Normal 6-35 repeats; expanded in disease
- Repressor domain: Interacts with HDACs
- Nuclear localization signals: For nuclear import
- Co-repressor activity: Recruits histone deacetylases
- Gene silencing: Represses target gene expression
- Chromatin remodeling: Modifies histone acetylation status
- Development: Essential for neuronal differentiation
- Synaptic plasticity: Regulates synaptic gene expression
- Cell survival: Anti-apoptotic functions
Pathogenic expansions cause:
- Polyglutamine toxicity: Expanded repeats cause protein aggregation
- Transcriptional dysregulation: Loss of normal repressor function
- Neuronal loss: Cerebellar, pallidal, and brainstem involvement
- Movement disorders: Ataxia, chorea, myoclonus
- Huntington's disease: Altered ATN1 expression
- Alzheimer's disease: Possible involvement in pathogenesis
- Other polyglutamine diseases: Shared mechanisms
| Strategy |
Description |
Status |
| ASO therapy |
Silence mutant ATN1 expression |
Research |
| HDAC inhibitors |
Restore transcriptional balance |
Preclinical |
| Aggregation blockers |
Prevent protein aggregation |
Experimental |
- ATN1 and DRPLA: Pathogenesis and therapy. Neurobiology of Disease.
- Polyglutamine expansion in ATN1. Human Molecular Genetics.
- Transcriptional repression in neurodegeneration. Trends in Pharmacological Sciences.
The study of Atn1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
ATN1 in DRPLA:
- Polyglutamine expansion: CAG repeat in ATN1
- Neurodegeneration: Progressive ataxia, dementia
- Anticipation: Earlier onset in successive generations
- Molecular mechanisms: Toxic polyglutamine aggregates
ATN1 involvement:
- Processing: Gamma-secretase cleavage
- Neuronal survival: Altered in AD
- Research tool: ATN1 cleavage as marker
- Huntington's disease: Similar polyglutamine mechanism
- Spinocerebellar ataxias: Overlapping pathways
- Motor neuron disease: Possible role
Atn1 knockout mice:
- Viable: Normal development
- Neurological phenotypes: Mild motor deficits
- Cellular changes: Altered neuronal morphology
- Polyglutamine expansion: DRPLA models
- Aggregate formation: Protein aggregation studies
- Therapeutic testing: Drug screening platforms
- Gene therapy: siRNA approaches
- Small molecules: Aggregate breakers
- Protein stabilization: Chaperone approaches
- Cellular pathways: Autophagy enhancement
- Biomarkers: ATN1 fragments as markers
- Clinical trials: No current DRPLA trials
- Stem cell models: Patient-derived neurons
ATN1 (Atrophin 1) is a transcriptional co-regulator protein that, when mutated, causes dentatorubral-pallidoluysian atrophy (DRPLA). The polyglutamine expansion leads to protein aggregation and progressive neurodegeneration. Understanding ATN1 function provides insights into broader neurodegenerative mechanisms.
- Nucifora FC, et al. (2003). Atrophin-1 in polyglutamine disorders. Brain Res Rev. PMID:12681927
- Wood JD, et al. (2000). Ataxin-1 and ATN1 in neurodevelopment. Hum Mol Genet. PMID:10735648
- Margolis RL, et al. (2005). Dentatorubral-pallidoluysian atrophy. Brain. PMID:15689361